Roche (ROG) PT Set at CHF 260 by Morgan Stanley

Morgan Stanley set a CHF 260 price target on Roche (VTX:ROG) in a research report report published on Friday, November 17th. The brokerage currently has a neutral rating on the healthcare company’s stock.

Several other brokerages have also weighed in on ROG. set a CHF 203 target price on Roche and gave the stock a sell rating in a research report on Friday, October 20th. Berenberg Bank set a CHF 260 target price on Roche and gave the stock a neutral rating in a research report on Tuesday, October 24th. Goldman Sachs Group set a CHF 325 target price on Roche and gave the stock a buy rating in a research report on Monday, September 11th. Baader Bank set a CHF 231 target price on Roche and gave the stock a neutral rating in a research report on Tuesday, September 12th. Finally, UBS set a CHF 260 target price on Roche and gave the stock a neutral rating in a research report on Thursday, October 19th. Three equities research analysts have rated the stock with a sell rating, eight have given a hold rating and eight have assigned a buy rating to the stock. Roche currently has an average rating of Hold and a consensus target price of CHF 261.32.

Roche (ROG) traded up CHF 1.70 on Friday, hitting CHF 246.80. The stock had a trading volume of 1,240,000 shares, compared to its average volume of 1,720,000. Roche has a 52 week low of CHF 219.10 and a 52 week high of CHF 273.

ILLEGAL ACTIVITY WARNING: This piece of content was reported by StockNewsTimes and is the property of of StockNewsTimes. If you are accessing this piece of content on another site, it was illegally stolen and republished in violation of US and international copyright & trademark legislation. The legal version of this piece of content can be viewed at https://stocknewstimes.com/2017/12/06/roche-holding-ltd-rog-given-a-chf-260-price-target-at-morgan-stanley-2.html.

About Roche

Roche Holding AG (Roche) is a research-based healthcare company. The Company’s operating businesses are organized into two divisions: Pharmaceuticals and Diagnostics. The Pharmaceuticals Division consists of two business segments: Roche Pharmaceuticals and Chugai. The Diagnostics Division consists of four business areas: Diabetes Care, Molecular Diagnostics, Professional Diagnostics and Tissue Diagnostics.

Analyst Recommendations for Roche (VTX:ROG)

Receive News & Ratings for Roche Holding Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Roche Holding Ltd. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply